pf-03893787
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2009 (NCT00856687)
Timeline
Indications
Mechanism of action
- Histamine H4 receptorANTAGONIST
HRH4 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CN[C@@H]1CCN(c2cc(NCC3CC3)nc(N)n2)C1- Mol. weight
- 262.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1915540 ↗
Also known as
- pf-03893787
- pf-03893787
- pf-03893787
- pf-3893787
- pf-3893787
- zpl-3893787
- zpl-3893787
- zpl-3893787
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02618616 | Phase 2 | Jan 1, 2016 | Ziarco Pharma Ltd |
| NCT02424253 | Phase 2 | May 1, 2015 | Ziarco Pharma Ltd |
| NCT00992342 | Phase 1 | Nov 1, 2009 | Pfizer |
| NCT00856687 | Phase 1 | Apr 1, 2009 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 1 | 2009 |
| Ziarco Pharma Ltd | For profit | 2 | 2 | 1 | 2015 |
2 organizations
Page 1 / 1